Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD09 in Female Participants With Persistent HPV16 Infection
NCT07536282Phase 2Not yet recruiting
- Sponsor
- Newish Biotechnology
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NWRD09 in HPV16 infection (HPV16), sponsored by Newish Biotechnology. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
NWRD09
03
Conditions
HPV16 infection (HPV16)
Beyond the preview
Go deeper on NCT07536282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07536282.